These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 34663413)

  • 1. Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy.
    Bono S; Feligioni M; Corbo M
    Mol Neurodegener; 2021 Oct; 16(1):71. PubMed ID: 34663413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis.
    Sarlette A; Krampfl K; Grothe C; Neuhoff Nv; Dengler R; Petri S
    J Neuropathol Exp Neurol; 2008 Nov; 67(11):1055-62. PubMed ID: 18957896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Overview of the Nrf2/ARE Pathway and Its Role in Neurodegenerative Diseases.
    Zgorzynska E; Dziedzic B; Walczewska A
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The principal molecular mechanisms behind the activation of Keap1/Nrf2/ARE pathway leading to neuroprotective action in Parkinson's disease.
    Chakkittukandiyil A; Sajini DV; Karuppaiah A; Selvaraj D
    Neurochem Int; 2022 Jun; 156():105325. PubMed ID: 35278519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIM16 protects from OGD/R-induced oxidative stress in cultured hippocampal neurons by enhancing Nrf2/ARE antioxidant signaling via downregulation of Keap1.
    Ren X; Yu J; Guo L; Ma H
    Exp Cell Res; 2020 Jun; 391(1):111988. PubMed ID: 32251645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders.
    Minj E; Yadav RK; Mehan S
    Curr Mol Med; 2021; 21(8):630-644. PubMed ID: 33430731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of COVID-19-induced cytokine storm by Keap1-Nrf2 system: a review.
    Singh E; Matada GSP; Abbas N; Dhiwar PS; Ghara A; Das A
    Inflammopharmacology; 2021 Oct; 29(5):1347-1355. PubMed ID: 34373972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF-κB and Keap1 Interaction Represses Nrf2-Mediated Antioxidant Response in Rabbit Hemorrhagic Disease Virus Infection.
    Hu B; Wei H; Song Y; Chen M; Fan Z; Qiu R; Zhu W; Xu W; Wang F
    J Virol; 2020 May; 94(10):. PubMed ID: 32161178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An FTLD-associated SQSTM1 variant impacts Nrf2 and NF-κB signalling and is associated with reduced phosphorylation of p62.
    Foster A; Scott D; Layfield R; Rea SL
    Mol Cell Neurosci; 2019 Jul; 98():32-45. PubMed ID: 30954537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALS-FTLD associated mutations of SQSTM1 impact on Keap1-Nrf2 signalling.
    Goode A; Rea S; Sultana M; Shaw B; Searle MS; Layfield R
    Mol Cell Neurosci; 2016 Oct; 76():52-58. PubMed ID: 27554286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease.
    Geertsema S; Bourgonje AR; Fagundes RR; Gacesa R; Weersma RK; van Goor H; Mann GE; Dijkstra G; Faber KN
    Trends Mol Med; 2023 Oct; 29(10):830-842. PubMed ID: 37558549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
    Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
    Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophilic nitro-fatty acids prevent astrocyte-mediated toxicity to motor neurons in a cell model of familial amyotrophic lateral sclerosis via nuclear factor erythroid 2-related factor activation.
    Diaz-Amarilla P; Miquel E; Trostchansky A; Trias E; Ferreira AM; Freeman BA; Cassina P; Barbeito L; Vargas MR; Rubbo H
    Free Radic Biol Med; 2016 Jun; 95():112-20. PubMed ID: 27012417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired antioxydative Keap1/Nrf2 system and the downstream stress protein responses in the motor neuron of ALS model mice.
    Mimoto T; Miyazaki K; Morimoto N; Kurata T; Satoh K; Ikeda Y; Abe K
    Brain Res; 2012 Mar; 1446():109-18. PubMed ID: 22353756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of oxidative stress in pathophysiology of rheumatoid arthritis: insights into NRF2-KEAP1 signalling.
    Kaur G; Sharma A; Bhatnagar A
    Autoimmunity; 2021 Nov; 54(7):385-397. PubMed ID: 34415206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoflavone biochanin A, a novel nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element activator, protects against oxidative damage in HepG2 cells.
    Liang F; Cao W; Huang Y; Fang Y; Cheng Y; Pan S; Xu X
    Biofactors; 2019 Jul; 45(4):563-574. PubMed ID: 31131946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent Regulation of Decidual Oxidative-Stress Response by NRF2 and KEAP1 in Preeclampsia with and without Fetal Growth Restriction.
    Mundal SB; Rakner JJ; Silva GB; Gierman LM; Austdal M; Basnet P; Elschot M; Bakke SS; Ostrop J; Thomsen LCV; Moses EK; Acharya G; Bjørge L; Iversen AC
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Keap1-Nrf2 signaling in health and diseases.
    Xiao JL; Liu HY; Sun CC; Tang CF
    Mol Biol Rep; 2024 Jul; 51(1):809. PubMed ID: 39001962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis.
    Mead RJ; Higginbottom A; Allen SP; Kirby J; Bennett E; Barber SC; Heath PR; Coluccia A; Patel N; Gardner I; Brancale A; Grierson AJ; Shaw PJ
    Free Radic Biol Med; 2013 Aug; 61():438-52. PubMed ID: 23608463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in developing noncovalent small molecules targeting Keap1.
    Barreca M; Qin Y; Cadot MEH; Barraja P; Bach A
    Drug Discov Today; 2023 Dec; 28(12):103800. PubMed ID: 37852355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.